From Johns Hopkins: Staging lymph node metastases from lung cancer in the mediastinum

J Thorac Dis. 2014 Mar;6(3):230-236.

Staging lymph node metastases from lung cancer in the mediastinum.

Terán MD, Brock MV.

Author information

• Division of Thoracic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Abstract

BACKGROUND:

The presence of tumor metastases in the mediastinum is one of the most important elements in determining the optimal treatment strategy in patients with non-small cell lung cancer. This review is aimed at examining the current strategies for investigating lymph node metastases corresponding to an "N2" classification delineated by The International Staging Committee of the International Association for the Study of Lung Cancer (IASLC).

METHODS:

Extensive review of the existing scientific literature related to the investigation of mediastinal lymph node metastases was undertaken in order to summarize and report current best practices.

CONCLUSIONS:

N2 disease is very heterogeneous requiring multiple modalities for thorough investigation. New research is now focusing on better identifying, defining, and classifying lymph node metastases in the mediastinum. Molecular staging and sub-classifying mediastinal lymph node metastases are being actively researched in order to provide better prognostic value and to optimize treatment strategies. Non-invasive imaging, such as PET/CT and minimally invasive techniques such as endobronchial and endoscopic ultrasound guided biopsy, are now the lead investigative methods in evaluating the mediastinum for metastatic presence.